Venture capital firm Sofinnova Partners has appointed a deep pharma and drug development expert as Partner, the company has announced. 

David Evans is a physician-scientist with deep pharma and drug development expertise. He joins from the Roche Venture Fund, where he previously served as Senior Investment Director. There, he built a strong track record of identifying and supporting high-impact life-sciences companies with a focus on Europe and the UK. 

His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. 

Evans will play a key role in delivering Sofinnova’s Crossover Strategy, helping specifically with late-stage private and public life-sciences investments. 

The company says his combination of clinical, scientific, and investment expertise will strengthens the firm’s ability to evaluate and support the most sophisticated opportunities across the healthcare landscape. 

“David is exactly the kind of investor we look for at Sofinnova — exceptional scientific grounding, real-world clinical experience, and a strong investment instinct built over years at the frontier of healthcare,” said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. “His appointment reflects our continued commitment to building a world-class team in the UK and across Europe, and we are delighted to welcome him to the partnership.” 

“Sofinnova has built a truly differentiated platform in European life-sciences venture capital and being part of the team is an exciting opportunity to back the most innovative companies at a pivotal stage of their development,” Evans said. “I am excited to bring my experience across clinical medicine, drug development, and investment to a team of this caliber, and look forward to contributing to Sofinnova’s mission of building transformative life-sciences companies in Europe and the UK.”